Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)

NCT02260505 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

136

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Stromal Tumors
Resected Gastrointestinal Stromal Tumors
Non-metastatic
High Risk of Recurrence
KIT Gene Mutation

Interventions

DRUG: Imatinib maintenance

Sponsor

Centre Leon Berard